5353 Delveinsight

AL-Amyloidosis-Pipeline-Insights

DelveInsight’s AL Amyloidosis Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the AL Amyloidosis domain. The AL Amyloidosis Pipeline Analysis report offers a 360° view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for AL Amyloidosis emerging therapies. The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.  Some of the key highlights from the AL Amyloidosis Pipeline report:

  • The available therapeutic options in the AL Amyloidosis landscape aim to slow the disease progression and not stop the disease to improve survival benefits. However, to overcome these challenges, a few companies are working robustly to identify the cause of disease and developing targeted therapy. Several major AL amyloidosis therapies are expected to enter the market by 2030.
  • Globally, some of the major companies involved in strengthening the AL Amyloidosis therapeutic pipeline include Sorrento Therapeutics, Caelum Biosciences, Takeda Oncology, Oncopeptides, and others. 
  • Some of the key pipeline therapies for AL Amyloidosis include STI-6129, Melphalan flufenamide, CAEL-101, Ixazomib, and others. 
  • Among different pipeline therapies, CAEL-101 is one of the most promising therapies expected to launch in the coming years. In August 2020, Caelum Biosciences initiated a double-blind, randomized, multicenter international Phase 3 study of CAEL-101 combined with the standard of care (SoC) for plasma cell dyscrasia (PCD) versus placebo combined with standard of care PCD treatment in patients with Mayo stage IIIa AL amyloidosis that have not received prior treatment.
  • Bristol-Myers Squibb is investigating elotuzumab, in combination with lenalidomide and dexamethasone, and the therapy is in phase II clinical studies. Elotuzumab (Empliciti) is an IgG1k immuno-stimulatory monoclonal antibody targeting the signaling lymphocytic activation molecule F7 (SLAMF7).
  • Oncopeptides AB has initiated phase I/II clinical studies for its drug candidate Melflufen (melphalan flufenamide) for the treatment of AL amyloidosis. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) alkylator that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.

Request for Sample @ AL Amyloidosis Pipeline Insights and Outlook AL Amyloidosis Pipeline Analysis: Drug Profile 

  • STI-6129
  • Melphalan flufenamide
  • CAEL-101
  • Ixazomib
  • Elotuzumab
  • Daratumumab

Dive deeper to know more @ AL Amyloidosis therapeutics and drugs pipeline Some of the Key Companies in the  AL Amyloidosis Therapeutics Space Includes

  • Sorrento Therapeutics
  • Caelum Biosciences
  • Takeda Oncology
  • Oncopeptides
  • Bristol-Myers Squibb
  • Janssen Biotech

AL Amyloidosis Pipeline Therapeutics Assessment

  • By Stage
    • Discovery
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Pre-registration
  • Product Types:
    • Monotherapy
    • Combination 
  • Molecule Types:  
    • Gene therapies
    • Small molecule
    • Vaccines
    • Polymers
    • Peptides
    • Monoclonal antibodies
  • Mechanism of Action:
    • Protease inhibitors 
    • Immunomodulatory 
    • Multiple kinase inhibitor
  • Route of Administration:
    • Infusion
    • Intradermal
    • Intramuscular
    • Intranasal
    • Intravaginal
    • Oral
    • Parenteral
    • Subcutaneous
    • Topical

Got queries? Reach out for more information @ AL Amyloidosis Drug Pipeline Assessment  Scope of the Report

  • Coverage: Global
  • Key Market Players: Sorrento Therapeutics, Caelum Biosciences, Takeda Oncology, Oncopeptides, Bristol-Myers Squibb, Janssen Biotech, and several others
  • Key Pipeline Therapies: STI-6129, Melphalan Flufenamide, CAEL-101, Ixazomib, Elotuzumab, Daratumumab, and many more. 

Table of Content 

1 Report Introduction
2 AL Amyloidosis 
3 AL Amyloidosis Current Treatment Patterns
4 AL Amyloidosis – DelveInsight’s Analytical Perspective
5 Therapeutic Assessment
6 AL Amyloidosis Late Stage Products (Phase-III)
7 AL Amyloidosis Mid Stage Products (Phase-II)
8 Early Stage AL Amyloidosis Products (Phase-I)
9 AL Amyloidosis Pre-clinical Products and Discovery Stage Products
10 Inactive Products
11 Dormant Products
12 AL Amyloidosis Discontinued Products
13 AL Amyloidosis Product Profiles
14 AL Amyloidosis Key Companies
15 AL Amyloidosis Key Products
16 Dormant and Discontinued Products
17 AL Amyloidosis Unmet Needs
18 AL Amyloidosis Future Perspectives
19 AL Amyloidosis Analyst Review
20 Appendix
21 Report Methodology

Know more of what’s covered in the AL Amyloidosis Pipeline Assessment report Key Questions Answered in the AL Amyloidosis Report

  • What are the current options for AL Amyloidosis treatment?
  • How many companies are developing therapies for the treatment of AL Amyloidosis? 
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of AL Amyloidosis?
  • How many AL Amyloidosis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of AL Amyloidosis?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the AL Amyloidosis market? 

Request for a Webex demo @ AL Amyloidosis Drug Pipeline and get a walk-through of our report  Latest Reports AL Amyloidosis Market Insight DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the AL Amyloidosis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). AL Amyloidosis Epidemiology Forecast DelveInsight’s AL Amyloidosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of AL Amyloidosis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Advanced Wound Care Market DelveInsight’s ‘Advanced Wound Care Market Insights, Competitive Landscape, and Market Forecast 2026’ report deliver an in-depth understanding of advanced wound care and the historical and forecasted advanced wound care market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Nocturnal Enuresis Market DelveInsight’s “Nocturnal Enuresis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nocturnal Enuresis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Primary Immunodeficiency Market DelveInsight’s “Primary Immunodeficiency Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Immunodeficiency market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Dementia with Diabetes Market DelveInsight’s “Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dementia with Diabetes market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Corneal Endothelial Dystrophy Market DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Healthcare Blogs By DelveInsight

About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect With Us at LinkedIn | Facebook | Twitter

Tags: AL Amyloidosis Market, AL Amyloidosis, AL Amyloidosis Epidemiology

Contact Information:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187